OMCL Stock Overview
Provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
OMCL passed our risk checks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Omnicell, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$31.35 |
| 52 Week High | US$55.75 |
| 52 Week Low | US$25.12 |
| Beta | 0.79 |
| 1 Month Change | -5.00% |
| 3 Month Change | -27.31% |
| 1 Year Change | 17.64% |
| 3 Year Change | -73.94% |
| 5 Year Change | -54.97% |
| Change since IPO | 229.65% |
Recent News & Updates
Omnicell (NASDAQ:OMCL) Seems To Use Debt Rather Sparingly
Apr 07
Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?
Mar 20Recent updates
Omnicell (NASDAQ:OMCL) Seems To Use Debt Rather Sparingly
Apr 07Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?
Mar 20Why Omnicell's (NASDAQ:OMCL) Earnings Are Better Than They Seem
Feb 14Omnicell Q4 Earnings: Ignore The Short-Term Noise
Feb 12Results: Omnicell, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 09Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 26% Below Their Intrinsic Value Estimate
Jan 28Little Excitement Around Omnicell, Inc.'s (NASDAQ:OMCL) Revenues
Nov 27Omnicell, Inc. Just Beat EPS By 43%: Here's What Analysts Think Will Happen Next
Nov 02Omnicell Q3 Earnings: Look At The Growth Segment
Nov 01Is It Time To Consider Buying Omnicell, Inc. (NASDAQ:OMCL)?
Oct 31Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?
Oct 07Omnicell, Inc.'s (NASDAQ:OMCL) Price Is Right But Growth Is Lacking After Shares Rocket 49%
Aug 02Is There Now An Opportunity In Omnicell, Inc. (NASDAQ:OMCL)?
Jul 11Benign Growth For Omnicell, Inc. (NASDAQ:OMCL) Underpins Its Share Price
Jun 16Omnicell (NASDAQ:OMCL) Is Making Moderate Use Of Debt
May 25An Intrinsic Calculation For Omnicell, Inc. (NASDAQ:OMCL) Suggests It's 29% Undervalued
Mar 28Omnicell, Inc.'s (NASDAQ:OMCL) 25% Dip In Price Shows Sentiment Is Matching Revenues
Feb 29Is It Too Late To Consider Buying Omnicell, Inc. (NASDAQ:OMCL)?
Feb 23Omnicell Is Building A Strong Moat
Feb 22Does Omnicell (NASDAQ:OMCL) Have A Healthy Balance Sheet?
Jan 15Benign Growth For Omnicell, Inc. (NASDAQ:OMCL) Underpins Its Share Price
Dec 25Is Omnicell, Inc. (NASDAQ:OMCL) Trading At A 48% Discount?
Dec 06Omnicell, Inc. (NASDAQ:OMCL) Analysts Just Slashed Next Year's Revenue Estimates By 14%
Nov 10Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 27% Undervaluation?
Sep 06Would Omnicell (NASDAQ:OMCL) Be Better Off With Less Debt?
Aug 08Why Omnicell, Inc. (NASDAQ:OMCL) Could Be Worth Watching
Jul 02A Look At The Fair Value Of Omnicell, Inc. (NASDAQ:OMCL)
Jun 08Investors Could Be Concerned With Omnicell's (NASDAQ:OMCL) Returns On Capital
Apr 29Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?
Apr 11At US$55.77, Is Omnicell, Inc. (NASDAQ:OMCL) Worth Looking At Closely?
Mar 23Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 42% Undervaluation?
Feb 28Returns On Capital Are Showing Encouraging Signs At Omnicell (NASDAQ:OMCL)
Jan 15We Think Omnicell (NASDAQ:OMCL) Can Stay On Top Of Its Debt
Jan 01Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 46% Undervaluation?
Nov 17Shareholder Returns
| OMCL | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 2.7% | 2.8% | 6.8% |
| 1Y | 17.6% | 2.9% | 5.9% |
Return vs Industry: OMCL exceeded the US Medical Equipment industry which returned 2.9% over the past year.
Return vs Market: OMCL exceeded the US Market which returned 5.9% over the past year.
Price Volatility
| OMCL volatility | |
|---|---|
| OMCL Average Weekly Movement | 6.2% |
| Medical Equipment Industry Average Movement | 9.0% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: OMCL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: OMCL's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 3,670 | Randy Lipps | www.omnicell.com |
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital; and specialized automated dispensing systems for hospitals, health systems, and post-acute care facilities. It also provides central pharmacy dispensing services; IV compounding services; turnkey solution designed to help health systems establish, manage, and optimize an entity-owned specialty pharmacy, as well as support onsite management of specialty pharmacy services, including payer contracting, staffing, licensing, and 340B program administration.
Omnicell, Inc. Fundamentals Summary
| OMCL fundamental statistics | |
|---|---|
| Market cap | US$1.48b |
| Earnings (TTM) | US$12.53m |
| Revenue (TTM) | US$1.11b |
117.0x
P/E Ratio1.3x
P/S RatioIs OMCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OMCL income statement (TTM) | |
|---|---|
| Revenue | US$1.11b |
| Cost of Revenue | US$636.73m |
| Gross Profit | US$475.51m |
| Other Expenses | US$462.98m |
| Earnings | US$12.53m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 06, 2025
| Earnings per share (EPS) | 0.27 |
| Gross Margin | 42.75% |
| Net Profit Margin | 1.13% |
| Debt/Equity Ratio | 27.4% |
How did OMCL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/15 22:56 |
| End of Day Share Price | 2025/04/15 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Omnicell, Inc. is covered by 26 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| K. Juhng | BB&T Capital Markets |
| William Sutherland | Benchmark Company |
| Raymond Myers | Benchmark Company |